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The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120SU 
plays an essential role in virus binding to target CD4+ T-cells and is a major vaccine target. Gp120 has 
remarkably high levels of N-linked glycosylation and there is considerable evidence that this “glycan 
shield” can help protect the virus from antibody-mediated neutralization. In recent years, however, it 
has become clear that gp120 glycosylation can also be included in the targets of recognition by some 
of the most potent broadly neutralizing antibodies. Knowing the site-specific glycosylation of gp120 
can facilitate the rational design of glycopeptide antigens for HIV vaccine development. While most 
prior studies have focused on glycan analysis of recombinant forms of gp120, here we report the first 
systematic glycosylation site analysis of gp120 derived from virions produced by infected T lymphoid 
cells and show that a single site is exclusively substituted with complex glycans. These results should 
help guide the design of vaccine immunogens.
The envelope glycoprotein spikes on HIV-1 virions are comprised of trimers of non-covalently associated 
gp120SU/gp41TM (transmembrane envelope protein, TM–abbreviations are defined in Supplementary Table S16) 
heterodimers which are produced by furin-mediated proteolytic cleavage of the gp160 glycoprotein precursor. 
The HIV-1 envelope glycoprotein (Env) has remarkable levels of N-linked glycosylation with about 50% of its 
mass being glycan-derived. This extensive glycosylation constitutes a “glycan shield” which helps to protect the 
virus from antibody-mediated neutralization. However, with the isolation and detailed characterization of mul-
tiple broadly neutralizing monoclonal antibodies (bnAbs) in recent years, it has become clear that the glycans 
themselves can be involved in Env recognition by such antibodies. Indeed, the glycans on gp120SU, which is the 
more densely glycosylated component of the heterodimer, appear to be essential constituents of the binding sites 
for some of the most potent of these bnAbs.
Depending on the isolate, gp120SU has about 25 N-glycosylation sites, many of which are clustered within, or 
in close proximity to variable domains of the protein. Two of the best characterized bnAbs, PG9 and PGT128, tar-
get glycans associated with the variable regions V1/V2 and V3, respectively1,2. Much is known about the glycosyl-
ation of a great many gp120 variants expressed using recombinant methods in a variety of cell lines3–7. Thus, it has 
been shown that recombinant gp120 (rgp120) is rich in both complex-type and oligomannose N-glycans, with the 
former predominating. For example, early work on rgp120 from isolate HIV-1IIIB, expressed in Chinese hamster 
ovary (CHO) cells as a truncated, secreted product, identified 24 occupied sites, 13 of which were substituted with 
complex glycans whilst 11 sites were mainly oligomannose6. More recently it has been shown that the glycosyla-
tion profile can differ substantially, depending on the host-cells from which the recombinant gp120 is produced7. 
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Nonetheless, the high abundance of complex-type glycans in rgp120 is preserved, irrespective of the host cell. 
This is in sharp contrast to what has been found for virion-derived gp120SU where glycan profiling experiments 
have shown that the oligomannose content varies substantially depending on the strain, and can constitute up to 
80% of the glycome8,9. High levels of oligomannose have also recently been found in HIV-1 envelope glycoprotein 
when expressed recombinantly as membrane anchored10 or soluble trimers11,12. In previous virion studies, limita-
tions in sample availability precluded systematic site-specific glycan analysis. Thus only the global glycan content 
was determined. Consequently the site occupancy knowledge gained from analysing recombinant gp120SU has 
not so far been compared with that from virion derived gp120.
Defining site specific glycosylation on the virion envelope-glycoprotein should facilitate the rational design of 
glycopeptide antigens as targets for HIV vaccine development. Fortunately, progress in deriving cell lines that pro-
duce HIV-1 particles with increased gp120 content and methods for purifying gp120 from virions, coupled with 
improvements in glycoproteomic technologies, means that defining site occupancy, although very challenging, is 
now a feasible goal. Here we report our systematic glycoproteomic investigation of site-specific N-glycosylation of 
gp120 purified from HIV-1 virions produced by an infected T lymphoid cell line. We show that 20 of the 24 glyco-
sylation sites in the gp120 are almost exclusively occupied with oligomannose glycans, two sites are a mixture of 
complex and hybrid glycans, one site carries a mixture of similar quantities of all three glycan classes, and one site 
is exclusively substituted with complex glycans. The latter is located in the V1 domain. Based on research on other 
HIV strains, this site is likely to be important for binding by the peptidoglycan (PGT) family of potent bnAbs.
Results
Production and purification of HIV-1 BaL/SUPT1-R5 Env for site-specific glycoanalysis of 
gp120. Previously, it was found that HIV-1 and simian immunodeficiency virus (SIV) virions, produced from 
various T-cell lines contain a calculated average of between 7 and 14 envelope glycoprotein (Env) trimers per 
virion13,14. We have now performed biological, molecular, and structural analysis of human immunodeficiency 
virus (HIV-1) virions produced from in vitro propagation in SUPT1-CCR5 cells. SDS-PAGE, immunoblot anal-
ysis and sequence analysis were used to characterize viral proteins. Gag (group antigens) and Env content were 
monitored with a sensitive, specific, calibrated fluorescent dye staining technique15. Virus was produced by inoc-
ulating SUPT1-CCR5 cells with HIV-1BaL obtained from the National Institutes of Health (NIH) AIDS Reagent 
Program. Following an initial cytopathic crisis, a long term outgrowth from the infected culture produced large 
amounts of virus, without evident cytopathology, associated with loss of CD4 expression on producing cells. Env 
sequence analysis of the virus produced by a cell line derived from this outgrowth culture, designated HIV1 BaL/
SUPT1-R5 [CLN204], revealed a substantially homogeneous virus population and identified changes, includ-
ing truncations in the transmembrane envelope protein that were associated with increased virion Env content 
(Fig. 1a,b). Determination of the Gag/Env ratio for viral samples harvested from early and late cultures was 
performed by fluorescence-based quantitation15. A merged image of a representative gel is presented in Fig. 1a. 
The masses of HIV-1 capsid protein p24 (p24CA) and gp120SU in the virion samples were then calculated by inter-
polation of integrated pixel densities for the test samples onto standard curves obtained from a dilution series 
of calibrated protein standards. Immunoblot analysis of early vs. long-term culture supernatants confirmed the 
presence of a truncated form of TM (~gp36) in the late culture compared to viral sample harvested early (only 
gp41) (Fig. 1c). This virus retained robust infectivity in both single cycle (TZM-bl cells) and spreading infection 
(SUPT1-R5 cells) and demonstrated X4/R5 dual tropism. Of note, a similar 100-amino acid truncation in the 
cytoplasmic tail of gp41 in HIV-1RF was described previously after in vitro passage16. While increased virion Env 
content13,17–19 with maintenance of infectivity is a well described phenomenon for SIVs with certain truncations 
in TM, it has been more challenging to derive robustly infectious HIV-1 viruses with increased virion Env content 
using similar truncations13,20,21.
HIV-1BaL gp120 purification for glycoanalysis. Virions derived from the HIV-1 BaL/SUPT1-R5 cell 
line [CLN204] were density gradient-purified and the virion-associated gp120 was partially purified by HPLC 
(Fig. 2). The HPLC fractions containing gp120 were then loaded onto a SDS-PAGE gel and gp120 was purified. 
After destaining, the gp120–containing bands were excised and transferred to tubes containing a 1% (v/v) acetic 
acid (aq.) solution. Approximately 260 μ g of gp120SU derived from virions produced by the HIV-1 BaL/SUPT1-R5 
cell line [CLN204] was purified for the purposes of these analyses.
Strategy for defining gp120 glycosylation. Mapping of all 24 N-glycosylation sites in gp120 was 
achieved by performing multiple glycomic and glycoproteomic analyses, each employing low microgram quan-
tities of sample. Acknowledging the limitations inherent in each of the different techniques we utilized, we 
employed multiple different, complementary methods to obtain a more comprehensive analysis. In the glycomic 
experiments, glycans were released from tryptic digests by PNGase F, PNGase A or Endoglycosidase H (Endo H) 
and were permethylated prior to matrix-assisted laser desorption ionization tandem time of flight mass spec-
trometry (MALDI-TOF-TOF MS and MS/MS) analysis. Glycoproteomic analyses exploited both off-line and 
on-line nano-liquid chromatography (LC)-MS/MS, with MALDI and electrospray (ES) ionisation, respectively. 
Samples for glycoproteomics included: (a) tryptic digests; (b) sequential tryptic and Endo H digests; (c) sequential 
tryptic, Endo H and chymotryptic digests; (d) tryptic, Endo H and Endoproteinase GluC (Glu-C) digests. The 
overall strategy is depicted in Fig. 3.
The majority of gp120 glycans are oligomannose. MALDI profiles of PNGase F and A digests 
were dominated by oligomannose glycans, with the most abundant having six to nine mannoses (Fig. 4a,b and 
Supplementary Fig. S1). Bi-, tri- and tetra-antennary complex type glycans were also observed. They were esti-
mated to contribute about 10–15% of the N-glycome. The complex type glycans were mainly core fucosylated and 
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their antennae were either uncapped or sialylated with a maximum of one, two or three sialic acids on the bi-, 
tri- and tetra-antennary structures, respectively. Glycoproteomic experiments (see later) suggested that hybrid 
glycans constitute a portion of the glycans at some sites. This was supported by a series of minor ions in the 
Endo H-derived N-glycome whose compositions were consistent with hybrid structures carrying non-capped or 
sialylated complex-type antennae (Fig. 4c).
Glycoproteomics of gp120BaL defines site occupancy. Table 1 and Supplementary Tables S1–S15 
document the large body of data acquired from the numerous glycoproteomic analyses that enabled us to deter-
mine the types of glycans present at all consensus sites in gp120BaL. Below we present a concise summary of our 
structural conclusions for each glycosite. For clarity and convenience we have grouped the sites according to the 
domains of gp120 in which they are found.
The C1 domain. This domain has a single site (N1) at Asn-87. MALDI and ES analysis of tryptic and Endo H 
digests showed that this site has exclusively oligomannose glycans (Man6–9GlcNAc2) with Man8 being the most 
abundant.
The V1 and V2 domains. Seven glycosites are found in the V1/V2 domains. Three of these (N2, N6 and N8) are 
contiguous to the two S-S bridges that underpin the V1/V2 loops. N4, N5, and N6 are clustered in the N-terminal 
half of the V1 loop and N7 is three residues away from the S-S bridge at the beginning of the V2 loop.
The dominant glycans at N2 (Asn-129) are the same as at N1 (Man6–9 GlcNAc2). However, unlike N1, this 
site has a tiny amount of non-sialylated complex-type glycans (estimated to be about 0.3%). Their compositions 
(Hex6–7HexNAc5–6Fuc0–1) correspond to tri- and tetra-antennary glycans.
N3 (Asn-135) was the only site found to be exclusively glycosylated with complex-type glycans. 
All were sialylated with compositions of NeuAc1Hex6HexNAc5Fuc1, NeuAc1Hex7HexNAc6Fuc1 and 
NeuAc2Hex7HexNAc6Fuc1, corresponding to tri- and tetra-antennary core fucosylated structures. The disialylated 
tetra-antennary glycan was the most abundant.
Sites N4 (Asn-140) and N5 (Asn-143) are located three residues apart within a single tryptic glycopeptide 
(NVTNTTSSSR) and could not be studied separately. Acquiring glycoproteomic data on the intact glycopeptide 
was challenging, probably due to its low hydrophobicity, and only weak data for oligomannose glycoforms were 
Figure 1. Virion-associated Env analysis. (a) A two-dye SYPRO-stained (total protein magenta, glycoproteins 
green) SDS-PAGE gel analysis of early (1) vs. long-term culture (2,3) of HIV-1BaL. Early HIV-1BaL was prepared 
from a short term passage culture using virus originally obtained from the NIH AIDS Research and Reference 
Reagent Program. Long-term samples were derived from the original cultures, after extended culture. Gel was 
calibrated with the gp120SU (200–12.5 ng) and purified p24CA (600–37.5 ng) standards. MW standards are found 
in lane 4. Positive control samples are found in lanes 5–7; SIVmac239,(5), HIV-1NL43 (6), HIV-1MN (7). (b) Table 
shows calculated Gag:Env ratios for the different virus preparations based on densitometric measurements 
normalized for molecular weights, and estimated average trimers per virion, assuming 1400 gag molecules per 
particle14. (c) mAb 4E10 anti-HIV-1 TM immunoblot analysis of early (2) vs. long-term (3) HIV-1BaL culture 
series; 1 is MW standards. Short term passage virus shows only full length TM. In contrast, long-term cultured 
virus shows a mixture of TM species including both full length gp41 and truncated ~gp36.
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obtained. Analysing Endo H digests by ES-MS/MS was more successful, however. Data were observed for three 
glycoforms of the truncated glycopeptide substituted with either two HexNAc residues, two HexNAcFuc moieties 
or one of each. Because Endo H cannot digest complex-type glycans, the HexNAc Fuc moieties must have orig-
inated from hybrid glycans. Therefore we conclude that N4 and N5 carry a mixture of oligomannose and hybrid 
glycans.
Like N4 and N5, sites N6 (Asn-159) and N-7 (Asn-163) are close to each other in the protein and were studied 
together. Their analysis was somewhat complicated by the presence of an I to K sequence variant at position 168 
which resulted in two tryptic glycopeptides being present in the digests: NCSFNITTGIR and NCSFNITTGK. 
Nevertheless high quality data were obtained showing that these two sites are oligomannose of aggregate compo-
sition Man14–18GlcNAc4.
The N8 (Asn-200) tryptic glycopeptide gave only weak data despite numerous experiments. Therefore minor 
glycoforms will not have been observed. Molecular ions were observed consistent with sialylated hybrid and 
Figure 2. HPLC fractionation of HIV-1 BaL/SupT1-R5 used to purify gp120. (a) HPLC was used to separate 
HIV-1 BaL/SUPT1-R5 after inactivation with aldrithiol-250–52 under non-reducing conditions using 206nm UV 
absorbance to detect proteins. Viral protein peaks (identified by SDS-PAGE gels, sequencing and immunoblot 
analysis) are labelled above the chromatograph. (b) Coomassie blue-stain of SDS-PAGE gel was used to analyse 
gp120SU corresponding fractions, with the molecular mass of standards denoted (Lane 1). Lane 2 represents 
pre-fractionated, long term cultured virus (1μ L). We analysed HPLC fractions (Lanes 3–5). (c) Coomassie blue 
stained SDS-PAGE gel following HPLC purification of gp120SU (lanes 2–4). Lanes 1 represent MW standards. 
The band containing gp120SU was excised for glycomic/gylcoproteomic analyses.
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non-sialylated complex-type glycans. The presence of hybrid glycans was confirmed by Endo H digests. There was 
no evidence for oligomannose at this site.
The C2 domain. Sites N9, N10 and N11 are found in the C2 domain. N9 (Asn-244) and N10 (Asn-265) are 
located in a large tryptic glycopeptide spanning residues 240 to 276. Their glycans are exclusively oligomannose 
with an aggregate composition of Hex12–19GlcNAc4 with Man8–9GlcNAc2 being the most abundant glycans. The 
Hex19 composition is predicted to result from incomplete removal of glucose from the precursor glycan.
N11 was found to be a mixture of oligomannose and hybrid (estimated 8:1 relative abundance). This site 
has Man5GlcNAc2 in addition to the Man6–9GlcNAc2 compositions observed at the previous sites. Also Man6–7 
GlcNAc2 are more dominant than Man8–9GlcNAc2. The hybrid structures have compositions Hex6HexNAc3, 
NeuAcHex5–6HexNAc3 and NeuAcHex6HexNAc3Fuc.
R
K
R
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Figure 3. Simplified workflow of the glycomic and glycoproteomic methodologies employed. The samples, 
in the form of isolated gp120 gel bands, were excised and proteolytically digested in-gel. The resultant peptides/
glycopeptides were then eluted and subjected to either a detailed glycomic workflow (upper half of the figure) or 
in-depth glycoproteomic analyses (lower half of the figure).
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The V3 “oligomannose shield” domain. N12 (Asn-292), N13 (Asn-298) and N14 (Asn-304) are located in a large 
tryptic glycopeptide spanning Cys-299, which, with Cys-333, constitutes the S-S bridge that defines the V3 loop. 
Their glycans are almost exclusively oligomannose with an aggregate composition of Man22–26GlcNAc6 with 
Man24GlcNAc6 dominating. An estimated up to 1% of the glycome of these three sites is hybrid. N15 (Asn-334) is 
on the opposite side of the V3 loop, next to the S-S bridge. Only oligomannose glycans were observed at this site: 
Man5–9GlcNAc2 with Man8–9GlcNAc2 dominating.
Figure 4. N-glycome of HIV-1 BaL gp120. MALDI TOF mass spectrum of N-glycans released after PNGase-F 
digest: (a) full range spectrum (m/z 1500–4300); (b) expanded region (m/z 2500–4300), highlighted in the full 
range mass spectrum. Signal abundance (relative intensity) is normalised to the most abundant ion (indicated 
on the right hand axis) of the specified mass range. Structural assignments were based on MS and MS/MS data 
and knowledge of N-glycan biosynthetic pathways. The satellite peaks near the major peaks are permethylation 
artefacts whilst the peaks which are labelled with an “x” are derived from known contaminants. (c) Tabulated 
MALDI TOF data for N-glycans released after Endo-H digest.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:32956 | DOI: 10.1038/srep32956
Site
Sequential 
BaL 
numbering
Relative 
to 
HXB2CG Tryptic Peptide
Observed Glycosylation Glycoproteomics Glycomics Supplem 
entary 
Table
High 
Mannose Hybrid Complex
RCM- 
T
RCM-T + 
Endo-H
RCM-T +  
C + Endo-H
RCM-T + 
 G + Endo-H
RCM-T + 
PNGase-F
RCM-T + 
PNGase-A
RCM-T + 
Endo-H
N1 N87 N88  87NVTENF NMWK96
Man 6-9  ✓ ✓ ✓ ✓ ✓ ✓ S1
N2 N129 N130 121LTPLCVT LNC TDLR134
Man 6-9 Hex7 HexNAc6 Fuc
Hex7 HexNAc6
Hex6 HexNAc5 Fuc ✓ ✓ ✓ ✓ ✓ ✓ S2
Hex6 HexNAc5
N3 N135 N136 135NATSR139
Hex7 HexNAc6 
NeuAc2 Fuc
Hex7 HexNAc6 
NeuAc Fuc ✓ ✓ ✓ ✓ S3
Hex6 HexNAc5  
NeuAc Fuc
N4 N140 N141 140NVTNT TSSSR149
Man 4-9  ✓ ✓ ✓ ✓ S4
N5 N143 N141c 140NVTNT TSSSR149
Man 4-9  ✓ ✓ ✓ ✓ S4
N6 N159 N156 159NCSFNI TTGI R169
Man 6-9   ✓ ✓ ✓ ✓ ✓ S5
N7 N163 N160 159NCSFNI TTGI R169
Man 6-9   ✓ ✓ ✓ ✓ ✓ S5
N8 N200 N197 196LISCNTSV IT QACPK210
 Hex6 HexNAc3 NeuAc Hex5 HexNAc4 Fuc ✓ ✓ ✓ ✓ ✓ ✓ S6
Hex5 HexNAc3 
NeuAc Fuc Hex6 HexNAc5 Fuc
Hex5 HexNAc3 
NeuAc
Hex6 HexNAc5 
Fuc2
N9 N244 N241
240GPCSNVSTVQ 
CTHGIRPVVS259 
260TQLLLNGSLA 
EEEVVIR276
Man 6-9  ✓ ✓ ✓ ✓ ✓ ✓ S7
N10 N262 N262
240GPCSNVS 
TVQ CTHGIRP 
VVS259 260TQLLLN 
GSLA EEEVVIR276
Man 6-9  ✓ ✓ ✓ ✓ ✓ ✓ S7
N11 N279 N276 277SENFTNN AK285
Man 5-9 Hex6 HexNAc3 NeuAc Fuc ✓ ✓ ✓ ✓ ✓ S8
Hex6 HexNAc3 
NeuAc
Hex5 HexNAc3 
NeuAc
Hex6.HexNAc3
N12 N292 N289
286IIIVQLNESV 
EINCTRPN 
NN305 306TR307
Man 6-9 Hex5 HexNAc3 ✓ ✓ ✓ ✓ ✓ ✓ S9
Hex6 HexNAc3
Hex5 HexNAc3 
NeuAc
Hex6 HexNAc3 
NeuAc
N13 N298 N295
286IIIVQLNESV 
EINCTRPNNN305 
306TR307
Man 6-9 Hex5 HexNAc3
Hex6 HexNAc3
Hex5 HexNAc3 
NeuAc ✓ ✓ ✓ ✓ ✓ ✓ S9
Hex6 HexNAc3 
NeuAc
N14 N304 N301
286IIIVQLNESV 
EINCTRPNNN305 
306TR307
Man 6-9 Hex5 HexNAc3
Hex6 HexNAc3
Hex5 HexNAc3 
NeuAc ✓ ✓ ✓ ✓ ✓ ✓ S9
Hex6 HexNAc3 
NeuAc
Con-
tin-
ued
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Site
Sequential 
BaL 
numbering
Relative 
to 
HXB2CG Tryptic Peptide
Observed Glycosylation Glycoproteomics Glycomics Supplem 
entary 
Table
High 
Mannose Hybrid Complex
RCM- 
T
RCM-T + 
Endo-H
RCM-T +  
C + Endo-H
RCM-T + 
 G + Endo-H
RCM-T + 
PNGase-F
RCM-T + 
PNGase-A
RCM-T + 
Endo-H
N15 N334 N332 330QAHCNLSR337 Man 5-9  ✓ ✓ ✓ ✓ ✓ S10
N16 N341 N339 340WNDTLNK346 Man 6-9   ✓ ✓ ✓ ✓ ✓ ✓ S11
N17 N357 N357 353EQFGNK358 Man 5-9
Hex6 HexNAc3 
NeuAc Fuc
Hex8 HexNAc7 
NeuAc Fuc
Hex6 HexNAc3 
NeuAc Hex8 HexNAc7 Fuc
Hex5 HexNAc3 
NeuAc Fuc
Hex7 HexNAc6 
NeuAc Fuc
Hex6 HexNAc3 Fuc Hex7 HexNAc6 Fuc
Hex5 HexNAc3 
NeuAc Hex7 HexNAc6
Hex6 HexNAc3 Hex6 HexNAc6 Fuc
Hex5 HexNAc3 Fuc Hex6 HexNAc5 NeuAc Fuc
Hex5 HexNAc3 Hex6 HexNAc5 Fuc ✓ ✓ ✓ ✓ ✓ S12
Hex5 HexNAc5 Fuc
Hex5 HexNAc4 Fuc
Hex5 HexNAc3 Fuc
Hex5 HexNAc4
Hex4 HexNAc4 Fuc
Hex4 HexNAc3 Fuc
Hex3 HexNAc3 Fuc
N18 N387 N386
364HSSGGDPEIV 
THSFNCGGEF383 
384FYCNSTQLFN 
STWNVTEESN403 
404NTVENNTITL PCR416
Man 5-9   ✓ ✓ ✓ ✓ ✓ ✓ ✓ S13
N19 N393 N392
364HSSGGDPEIV 
THSFNCGGEF383 
384FYCNSTQLFN 
STWNVTEESN403 
404NTVENNTITL PCR416
Man 5-9   ✓ ✓ ✓ ✓ ✓ ✓ ✓ S13
N20 N397 N397
364HSSGGDPEIV 
THSFNCGGEF383 
384FYCNSTQLFN 
STWNVTEESN403 
404NTVENNTITL PCR416
Man 5-9   ✓ ✓ ✓ ✓ ✓ ✓ ✓ S13
N21 N403 N406
364HSSGGDPEIV 
THSFNCGGEF383 
384FYCNSTQLFN 
STWNVTEESN403 
404NTVENNTITL PCR416
Man 5-9   ✓ ✓ ✓ ✓ ✓ ✓ ✓ S13
N22 N408 N411
364HSSGGDPEIV 
THSFNCGGEF383 
384FYCNSTQLFN 
STWNVTEESN403 
404NTVENNTITL PCR416
Man 5-9   ✓ ✓ ✓ ✓ ✓ ✓ ✓ S13
N23 N445 N448 442CSSNITGLLL TR453 Man 5-9 ✓ ✓ ✓ ✓ ✓ S14
N24 N460 N463 454DGGPEDNKTE VFRPGGGDMR473
 Hex6 HexNAc3 NeuAc Fuc Hex7 HexNAc6 Fuc
Hex5 HexNAc3 
NeuAc Fuc Hex6 HexNAc5 Fuc
Hex6 HexNAc3 Fuc Hex5 HexNAc5 Fuc
Hex5 HexNAc4 Fuc ✓ ✓ ✓ ✓ ✓ ✓ S15
Hex4 HexNAc4 Fuc
Hex4 HexNAc3 Fuc
Hex3 HexNAc3 Fuc
Table 1.  Summary of observed site-specific glycosylation of HIV-1 BaL gp120. Sites of glycosylation are listed 
as sequential numbers (N1-24), as sequential residue numbering with respect to the BaL sequence and with respect 
to HXB2CG (see Fig. 5). The theoretical tryptic peptide with the consensus site highlighted is also listed, with sub 
digest peptides used in further analyses utilising additional digestions detailed in Supplementary Tables S1-15. 
The observed glycosylation is summarised for each individual site (“Man” indicates an oligomannose structure of 
composition Hex5-9HexNAc2) with the specific glycomic and glycoproteomic experimental evidence used per site 
indicated. Supplementary Tables S1-15 provide detailed assignments. The abbreviations used are–RCM (reduced 
and carboxymethylated), T (trypsin), C (Chymotrypsin), G (Glu-C), PNGase (peptide-N-glycosidase), Man 
(Mannose), Hex (Hexose), HexNAc (N-acetylhexosamine), NeuAc (N-acetylneuraminic acid), Fuc (Fucose).
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The C3 domain. There are two glycosylation sites in this domain. The first, N16 (Asn-341), carries oligoman-
nose glycans (Man6–9GlcNAc2) only, whilst the second (N17; Asn-357) has a more diverse array of glycans. All 
three classes of glycans were observed at this site (oligomannose, complex and hybrid) and no class dominates. A 
complete list of glycan compositions is given in Table 1. The most abundant glycans observed were Man7GlcNAc2 
(oligomannose), Hex6HexNAc5Fuc (non-sialylated complex) and NeuAcHex5-6HexNAc3Fuc (sialylated hybrid).
The V4 domain. This domain is very heavily glycosylated in the gp120 analysed here having 5 glycosites in the 28 
amino acid (AA) loop formed by the S-S bridge between Cys-387 and Cys-415. The glycosites are N18 (Asn-387), 
N19 (Asn-393), N20 (Asn-397), N21 (Asn-403) and N22 (Asn-408). There are no tryptic cleavage sites in this 
domain and the large tryptic glycopeptide spanning His-364 to Arg-416 was not observed. Glycopeptide data 
were, nevertheless, successfully obtained on Endo H digests of chymotryptic and Glu-C sub-digests of the tryptic 
glycopeptide. HexNAc was observed at each site indicating that N18 to N22 are predominantly substituted with 
oligomannose glycans. The possibility that some of the glycans are hybrid cannot be ruled out, although the very 
low abundance of hybrid glycans in the Endo H glycomics data means that, if present, they are very minor.
The C-terminal domain. The polypeptide on the C-terminal side of the V4 loop is largely conserved in gp120s 
except for a small variable domain (V5) after the last S-S bridge. N23 (Asn-445) is located in a conserved part of 
the sequence three residues from this bridge. N24 (Asn-460) is 15 AA residues further down the sequence and is 
within the V5 domain. The former has exclusively oligomannose glycans (Man5–9GlcNAc2) with Man8–9GlcNAc2 
being most abundant. In contrast, the latter (N24) is decorated with complex-type and hybrid glycans. Sialic acid 
is present on some of the hybrid glycans but not the complex glycans (Table 1).
Discussion
The focus on HIV-1 Env as a vaccine target, and the development and detailed characterization of bnAbs directed 
against HIV-1gp120, including potent bnAbs that include glycans as part of their recognition sites, have increased 
interest in better understanding the glycan composition of this heavily glycosylated viral protein. However, until 
now, all of the experiments used to comprehensively characterise the site specific N-glycosylation of this glyco-
protein have been based on analyses of recombinant expressed forms of gp120. Characterization of site-specific N 
glycosylation of gp120 derived from HIV-1 virions, the actual target of bnAbs, should allow a better understand-
ing of what these bnAbs actually are recognising, and may facilitate the development of improved glycan-binding 
bnAbs and/or Env based vaccine immunogens.
In this study we determined the types of N-linked glycans that are present on each of the 24 N-glycan con-
sensus sites of gp120 derived from virions produced by the HIV-1 BaL/SUPT1-R5 cell line [CLN204]. The char-
acterisation of such a high number of glycosylation sites on a glycoprotein which could not be readily isolated in 
analysable quantities, was exceptionally challenging. We achieved this by employing an integrated glycomics and 
glycoproteomics strategy which takes advantage of the inherent specificity of three endo-glycosidases (PNGase F, 
PNGase A and Endo H), three proteases (trypsin, chymotrypsin and Endoproteinase Glu-C) and the application 
of both MALDI- and electrospray mass spectrometry.
In terms of overall glycan content, the virion derived gp120SU we analysed is predominantly glycosylated 
with oligomannose structures which are mainly Man9GlcNAc2 (≈ 40%) and Man8GlcNAc2 (≈ 40%) with lesser 
amounts of Man7GlcNAc2 (≈ 15%), Man6GlcNAc2 (< 5%) and Man5GlcNAc2 (< 1%) (Fig. 4a). We also found 
significant quantities of complex-type glycans (10–15% of total glycome) together with minor amounts of hybrid 
N-glycans (< 5% of total glycome) (Fig. 4a,b). The majority of the complex glycans are core fucosylated, sialylated 
and highly branched. Thus bi-, tri- and tetra-antennary glycans comprise about 15%, 40% and 45% of the 
complex-type glycome, respectively (Fig. 4b). The most abundant hybrid glycan is sialylated (Fig 4c). These results 
are broadly in line with previous glycomic investigations of viral derived gp1208,17,22 (reviewed in Doores et al.18). 
Scanlan and colleagues were the first to show marked differences between virion and recombinant gp1208,17. 
They found oligomannose contents of 56–79%, depending on the strain, which were substantially higher than the 
30% expressed on recombinant material. This early work suggested that Man5GlcNAc2 was the most abundant 
oligomannose glycan in gp120JRCSF. However, a recent study by Pritchard et al. has shown that Man7–9GlcNAc2 
compositions are actually the most abundant oligomannose components in this strain22. Our observations for the 
BaL strain are in accord with this result. Pritchard et al.22 employed ion mobility mass spectrometry to study the 
complex-type glycans in gp120JRCSF and they found that the majority were sialylated multi-antennary structures. 
We have identified a similarly restricted repertoire in BaL. None of the aforementioned publications reported the 
presence of hybrid glycans on virion-derived gp120. Whether this is due to strain-specific expression of hybrid 
glycans, or to differing capabilities of the analytical methods used in the various studies, remains to be established.
Our work constitutes the first systematic glycoproteomic analysis of any virion-derived gp120 to include site 
specific analysis. Other workers23 have previously applied glycoproteomic methods to viral gp120 but the focus 
of their work was the development of an automated spectral-aligning strategy and they only reported on five gly-
cosylation sites. As shown in Fig 5, the virion-derived gp120 we studied has 24 N-glycosylation sites. Compared 
to the canonical HIV-1HXB2 strain, it is missing 3 N-glycosylation sites in and near the V2 loop and has an addi-
tional site in the V1 loop (Fig. 5). Thirteen sites are exclusively occupied with oligomannose glycans (Fig.5; dark 
green annotations). An additional seven sites are almost entirely oligomannose together with a trace (< 0.3%) 
of non-sialylated complex structures (Asn-129) or low levels (< 1%) of hybrid structures (Asn-140, Asn-143, 
Asn-279, Asn-292, Asn-298 and Asn-304). Complex-type glycans are found in substantial amounts at four sites. 
Two of these, Asn-200 and Asn-460, additionally carry hybrid structures, although oligomannose glycans are 
not present. A single site, Asn-357, carries oligomannose, complex and hybrid glycans. All three glycan classes 
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are present at this site in comparable amounts. Finally, one site, Asn-135, is exclusively occupied with sialylated 
multiantennary complex glycans.
Much of current research aimed at understanding how broadly neutralising antibodies can penetrate the gly-
can shield of the HIV-1 envelope exploits recombinant Env trimers24,25. Although no trimer glycoproteome has 
yet been comprehensively mapped, information is available for about 75% of the glycosites in the soluble trimer 
BG505 SOSIP.664 expressed by HEK293T cells11,12. Thus, Behrens et al. quantified glycan populations at 17 of 
the 24 N-glycosites in the gp120 portion of this trimer. Ten sites were found to be exclusively occupied with 
oligomannose (Asn-156, Asn-234, Asn-262, Asn-295, Asn-332, Asn-339, Asn-363, Asn-386, Asn-392 and Asn-
448; numbering corresponds to BG505 SOSIP.664), one site was mostly oligomannose with low levels of hybrid 
and complex (Asn-276), one site was occupied with both oligomannose and complex (Asn-160), three sites were 
mostly complex with low levels of oligomannose and hybrid (Asn-88, Asn-190 and Asn-462), and two sites were 
occupied with substantial quantities of all three classes of glycan (Asn-197, Asn-355). The main conclusions 
that can be drawn from comparison of the glycoproteomics data from the virion BaL and recombinant BG505 
trimer are (i) the unprocessed oligomannose “patch” centred on the V3 domain is shared by both samples, and 
(ii) the recombinant trimer has substantially higher levels of complex glycans than virion BaL. Thus, Asn-88 is 
occupied mainly by complex glycans in the recombinant trimer whilst it is exclusively oligomannose in virion 
BaL (Asn-87); Asn-160 carries about 30% complex glycans in the recombinant BG505 trimer but none in BaL 
(Asn-163); Asn-190, which is almost entirely occupied with complex glycans in the trimer, is not a glycosite in 
BaL. Unfortunately the site that is exclusively occupied with multi-antennary complex glycans in virion BaL (Asn-
135) was not characterised in the recombinant trimer study (Asn-137), so no conclusions relating to antibody 
recognition of this site can be drawn from the glycoproteomic comparisons.
The N-glycan site specific characterisation of virion-derived gp120 will be of great value in allowing a bet-
ter understanding of the actual binding partners of a range of important bnAbs (Reviewed in Doores et al.18). 
The unusual domain exchanged 2G12 bnAb has been demonstrated to recognize Manα 1,2Man-linked sug-
ars of oligomannose glycans (Man8–9GlcNAc2) associated with sites N-295, N-332, N-339 and N-392 of the so 
called high-mannose patch of V326,27. This is fully consistent with our present glycoproteomics data, which show 
that all these sites (N-298, N-334, N-341 and N-393) express Man8-9GlcNAc2 N-glycans. Additional bnAb such 
as PGT121–123 also bind the high mannose patch and N-332 as well as overlapping epitopes. The binding of 
PGT121–123 can include the Man8–9GlcNAc2 N-glycan at N-332 and associated glycans in the V1/V2 loops 
Figure 5. Visual representation of the HIV-1BaL gp120 secondary structure. Residue numbers for N-linked 
glycosylation sites are listed as both sequential numbering with respect to the experimentally deduced BaL 
sequence, and with the numbering with respect to the reference HIVHXB2 indicated in brackets. Individual 
sites are indicated as orange circles, with the sequential site number (1–24) shown within the circle. The three 
consensus sites of HXB2CG not present in this swarm are indicated with empty circles. The general type of 
glycosylation (high mannose, complex, hybrid) observed at each site is indicated by colour coding, with the key 
given within the figure.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:32956 | DOI: 10.1038/srep32956
such as N-136 and N-156. Binding of PGT121–123 to viruses produced in N-acetylglucosaminyltransferase 1 
(GnT1)−/− cells, which only express oligomannose N-glycans, indicates little or no requirement for complex 
type glycans. However, if the N-332 glycan is absent a requirement for complex glycans in V1/V2 sites such as 
N-136 and N-156 was deemed to be important28. As indicated above, our data show that N-334 does express 
Man8–9GlcNAc2 N-glycans. Also consistent with these observations is that N-135 (equivalent to N-136) expresses 
exclusively complex type N-glycans. However, N-159 (equivalent to N-156) expresses oligomannose N-glycans 
and no complex glycans were detected at this site.
A family of bnAb, including PG9 and PG16, have been described that bind the trimer apex of the V1/V2 area 
which include the N-160 glycosylation site. X-ray crystallographic structural studies of protein scaffolds of the 
V1/V2 region with bound PG9 demonstrated the critical importance of a Man5GlcNAc2 N-glycan structure at 
N-160. Additional interactions with the protein bound GlcNAc of the N-glycans at N-156/173 were also indicated 
to be important29. Subsequent structural analysis of PG9 and PG16 interacting with protein scaffolds of the V1/
V2 region also demonstrated the importance of oligomannose type glycans (at least Man5GlcNAc2) at N-160 but 
showed binding of a sialylated complex or hybrid N-glycan at N-156/17330. Our data show the equivalent site of 
N-160 on the gp120 we studied, N-163, is substituted with oligomannose glycans. In this gp120 the equivalent site 
to N-173 does not contain an N-glycosylation site and the equivalent site to N-156 (N-159) contains oligoman-
nose glycans. There was no evidence for complex N-glycans at either N-159 or N-163 in BaL.
An additional set of bnAb, for example VRCO1, recognize the CD4 binding site on gp120. X-ray crystal-
lography studies with recombinant gp120 and VRCO1 have demonstrated interactions with the protein bound 
GlcNAc of the N-glycans at N-276. To facilitate crystallization of the gp120, Endo H digestion was used which left 
only a GlcNAc or possibly GlcNAcFuc residues, which indicate that the N-glycans at site N-276 must be either 
oligomannose or hybrid glycans31. This is fully consistent with our current data which indicate that the equivalent 
glycosylation site N-279 expresses both oligomannose and core fucosylated hybrid N-glycan structures.
In conclusion, we have achieved the first systematic glycosylation site analysis of a gp120 derived from virions 
produced by infected T lymphoid cells. This is an important achievement because the strategies we have opti-
mised constitute the blueprint for future comparative characterization of a variety of virion derived envelope 
glycoproteins of different virus isolates from different cell sources. Such analyses should provide insights into 
optimizing the design of immunogens as well as methods and reagents for evaluation of neutralizing antibodies, 
including those generated in response to vaccination.
Methods
Derivation of the HIV-1 BAL/SUPT1-CCR5 CL.30 cell line. All work was performed using asep-
tic techniques in a biosafety level 2 laboratory following biosafety level 3 practices. The cell line, HIV-1 BAL/
SUPT1-CCR5 CL.30, designated cell line number 204 (CLN204), was derived by infecting the SUPT1-CCR5 
CL.30 cell line CLN195 which is a limiting dilution clone of the SUPT1-CCR5 cell line previously described32 
with an infectious virus stock of HIV-1 BAL/Human peripheral blood lymphocytes (PBL) obtained from the 
NIH AIDS Reagent Program (cat.# 510, lot # 97116). The HIV-1 BAL/SUPT1-CCR5 CL.30 cell line is a bulk 
HIV-1 infected cell line. SUPT1-CCR5 CL.30 cells were propagated using RPMI1640 supplemented with 10% 
Fetal Bovine Serum (heat-inactivated), 100 units/mL Penicillin and 100 μ g/mL Streptomycin (complete medium) 
in T flasks and passaged 1:3 twice weekly. CCR5 transgene expression by SUPT1-CCR5 CL.30 cells is under 
Puromycin selection (0.3 μ g/mL), although Puromycin selection was not required to maintain CCR5 expression. 
The cell density was typically ~1.0 × 106 viable cells/mL and > 90% viability at each passage. The fluorescence-ac-
tivated cell sorting (FACS) immunophenotype of these cells was found to be essentially 100% CD4 and CXCR4 
positive with an average of 67% CCR5 positive. Cells were 100% human leukocyte antigen (HLA) Class I positive 
and HLA Class II negative.
For infection, a cell pellet consisting of 1.5 × 107 viable SUPT1-CCR5 CL.30 cells was prepared by centrifu-
gation at ~600 × g in a 15 mL polypropylene tube and inoculated with 0.5 mL of the HIV-1 BaL infectious stock. 
An equal volume of complete media containing 4 μ g/mL polybrene was added to achieve a final concentration of 
2 μ g/mL polybrene and the cells incubated at 37 °C for 2 hours. The cells were transferred to a T75 flask containing 
30 mL of complete media containing 2 μ g/mL polybrene and the culture incubated at 37 °C in 5% CO2 overnight. 
Polybrene and unbound virus were removed from the cells by centrifugation as described above. The cell pellet 
was transferred to a new T75 flask containing 30 mL of complete media and returned to the incubator. This cul-
ture was passaged twice weekly and monitored for progeny virus production using an in-house HIV-1 p24CA anti-
gen capture immunoassay. By day 4 post infection (PI), virus induced cytopathic effects (CPE) were evident and 
both the cell density and viability were declining. To maintain culture viability and increase virus yield, ~500,000 
non-infected SUPT1-CCR5 CL.30 cells were added per mL of culture. At the next three passages, non-infected 
cells were also required and added after which the culture was allowed to undergo crisis during which the culture 
viability dropped to 2%. By day 42 PI a stable, productively infected, CPE-free cell line arose that when passaged 
twice weekly at 1:3 yielded ~1.0 × 106 viable cells/mL and > 90% viability. This cell line has been cultured for over 
85 passages in T flasks and consistently provided 1–2 × 103 ng/mL HIV-1 p24CA as assessed by antigen capture 
immunoassay, ~1.0 × 106 viable cells/mL and > 90% viability at the day of passage. The flow cytometric immu-
nophenotype of this cell line is CD4 negative, CCR5 negative, 100% CXCR4 positive, and typically > 85% intra-
cellular HIV-1 gag positive. It is also 100% HLA Class I positive and HLA Class II negative.
Viral tropism assay. HIV-1 co-receptor usage was determined by inoculating a trio of CD4 expressing 
cell lines derived from SUPT1 cells which express either: no co-receptor, the CXCR4 co-receptor or the CCR5 
co-receptor33. Cell cultures were inoculated with non-concentrated virus stocks and monitored for virus infec-
tion by observing for cytopathic effects and by HIV-1 p24CA antigen capture immunoassay for up to three weeks. 
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Substantial cytopathic effects and/or increasing HIV-1 p24CA concentrations were used to detect infection and 
thus determine co-receptor usage for the virus tested.
TZM-bl Assay. The TZM-bl cell line, initially referred to as JC53BL cells, were obtained from the NIH AIDS 
Reagent Program (Cat.# 8129) and propagated as monolayers in T-flasks essentially as previously described. 
Infection of this cell line with HIV-1 results in the trans-activating transcriptional activator (TAT) driven expres-
sion of β -galactosidase and luciferase reporter cassettes. Infectious titres of HIV-1 in culture supernatant samples 
were determined using 96 well plates seeded with 1.0 × 104 viable TZM-bl cells per well in 100 μ l of phenol red 
free-RPMI1640 media containing 10% foetal bovine serum (heat inactivated), 2 mM L-glutamine, and 100 U/mL 
penicillin and 100 μ g/mL streptomycin (= assay media). Plates seeded with these cells were incubated at 37 °C 
in 5% CO2 for 3 to 18 hours to allow the cells to attach. Serial, 3-fold dilutions of samples were prepared in 
assay media. After aspirating the culture supernatant, duplicate (100 μ l) samples of each dilution were added 
and the plate(s) incubated for 72 hours at 37 °C in 5% CO2. The presence of replicating HIV-1 was detected via 
the β -galactosidase reporter cassette. After aspirating the culture supernatant, 100 μ l of a solution containing 1% 
Triton X-100, 1.5 mM Chlorophenol Red-β -Galactopyranoside (Roche cat.# 10884308001), and 0.12% NuPAGE 
reducing agent (Life Technologies cat.# NP0004) in DPBS containing calcium and magnesium was added to each 
well. Colour development was allowed to proceed for 1 hour while incubating at 37 °C and the absorbance of 
each well determined using a microplate reader (Molecular Devices VMax® ). Reciprocal titres were determined 
by interpolation between the average absorbance of the two reciprocal dilutions that bracketed the arbitrary 1.0 
absorbance unit cut-off. An aliquot of a positive control HIV-1 infectious stock sample (stored at − 80 °C) was 
rapidly thawed in a 37 °C water bath and its titre determined in each assay to monitor for assay reproducibility.
Determination of infectious titre. Serial, ten-fold dilutions of culture supernatant samples containing 
HIV-1 were prepared in complete media and a 1 mL portion of each dilution added to a 5.0 × 106 cell pellet 
of SUPT1-CCR5 CL.30 cells in a sterile 15 mL polypropylene tube. The cell pellets were gently resuspended in 
their respective samples and, after incubation at 37 °C for an hour, transferred to T25 flasks containing 9 mL of 
complete media. Cultures were incubated at 37 °C in 5% CO2 and split 1:2, twice weekly. The concentration of 
HIV-1 p24 in them was determined by HIV-1 p24 antigen capture immunoassay every 7 days for 21 days. Sample 
infectious titre was defined as the greatest reciprocal dilution resulting in a positive HIV-1 p24 antigen capture 
immunoassay result.
Large scale production and purification of virus. In brief, large scale culture propagation was per-
formed using 850 cm2 roller bottles containing 400 mL of culture in complete media. Cultures were harvested and 
passaged 1:2 twice weekly. Cells were removed from harvested material by 5.0 μ m capsule filtration (Millipore 
Polygard CN Opticap XL10, Cat. No. KN50A10HH1). The virus from up to 30 litre batches of culture filtrate was 
purified and concentrated by continuous flow-sucrose density gradient centrifugation in a 25 to 50% sucrose in 
Tris/NaCl/EDTA (TNE) gradient using a Beckman CF32 rotor at 30,000 rpm at 4 °C with a flow rate of less than 6 
litres per hour. Virus containing sucrose density gradient fractions were diluted to less than 20% sucrose and the 
sucrose removed by direct pelleting the virus in a fixed angle Beckman TY45 rotor at 30,000 rpm for 1 hour at 4 °C. 
The virus pellet was resuspended in sterile TNE at a final concentration of 1000x (i.e. 1 litre of cell culture yielded 
1 mL of purified virus) and 250 μ l aliquots were stored in liquid N2 vapour. Typical lots contained ~2.6 mg/mL 
of total protein (Bio-Rad DC Assay) and between 0.3 and 0.5 mg/mL capsid protein. The purified virus lots P4235, 
P4236, P4238 and P4239 were used for the glycan experiments.
Viral genetic analysis. Single genome amplification (SGA) was utilized to generate unique, independent 
sequences from cultured HIV-1 BaL/SUPT1-CCR5 cells, as previously described34. The entire 3′ half of the viral 
genome (including the entire vif, vpr, vpu, tat, rev env and nef genes) was amplified from DNA (Qiagen DNA 
Blood kits). PCR was performed using a limiting dilution approach where only one amplifiable molecule was 
present in each reaction. PCR was performed with 1 × PCR buffer, 2 mM MgCl2, 0.2 mM of each deoxynucleoside 
triphosphate, 0.2 μ M of each primer, and 0.025 U/μ L Platinum Taq polymerase (ThermoFisher) in a 20 μ L reac-
tion. First round PCR was performed with sense primer HIVBK3F1 5′ -ACAGCAGTACAAATGGCAGTATT-3′ 
and antisense primer HIVR3B3.R1 under the following conditions: 1 cycle of 94 °C for 2 min, 35 cycles at 
94 °C for 15 sec, 55 °C for 30 sec, and 72 °C for 4 min, followed by a final extension of 72 °C for 10 min. Next, 
1 μ L from the first-round PCR product was added to a second-round PCR reaction that included the sense 
primer HIVBK3F2 5′ -TGGAAAGGTGAAGGGGCAGTAGTAATAC-3′ and antisense primer HIVR3B6.R2 
5′ -TGAAGCACTCAAGGCAAGCTTTATTGAGGC-3′ performed under the same conditions used for 
first-round PCR, but with a total of 45 cycles. Correct sized amplicons were identified by agarose gel electropho-
resis and directly sequenced with second round PCR primers and HIV specific primers using BigDye Terminator 
technology. Sequences were aligned using ClustalW and hand edited using MacClade 4.08. The entire gp160 
amino acid alignment is shown in Fig. 6.
Sypro Dual colour fluorescent protein gel analysis. Proteins from lysed virus preparations were 
resolved by SDS-PAGE on 4–20% Tris-glycine gels (Invitrogen) under reducing conditions. The p24 and gp120 
content of the samples were determined by a two-colour fluorescence staining assay. Gels with virus samples 
and a dilution series of purified protein standards were stained with two fluorescent dyes (Molecular Probes, 
Eugene, OR), SYPRO Pro-Q Emerald (green fluorescence) to detect glycoproteins, such as Env, and SYPRO Ruby 
(red fluorescence) to detect all proteins, including p24. Stained gels were analysed for fluorescence at 520 nm with 
UV excitation, using a VersaDoc 3000 Imaging System (Bio-Rad Laboratories, Hercules CA) software package 
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(Bio-Rad Laboratories) by interpolating the integrated pixel density signals from the unknown samples onto a 
standard curve derived from a linear regression of density values for serial dilutions of highly purified, quantita-
tive amino acid analysis quantified standards, either recombinant vaccinia-produced HIV-1MN gp120SU (gener-
ously provided by Drs. B. Puffer and R. Doms, University of Pennsylvania, Philadelphia, PA) or HIV-1MN virion 
derived p24CA (AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD). Well char-
acterized reference preparations of SIVmac239/SUPT1-R5 and HIV-1MN /H9 Clone 4 (AIDS and Cancer Virus 
Program, Frederick National Laboratory, Frederick, MD) were used to validate this procedure15,35.
Reverse-phase high performance liquid chromatography (RP-HPLC) purification of viral gp120 
proteins. Viral samples were disrupted in 8 M Guanidine-HCl (Pierce, Rockford, IL) and fractionated under 
non-reducing conditions by HPLC to isolate viral gp120 protein. HPLC was performed at a flow rate of 300 μ L/min 
on 2.1 × 100 mm Poros® R2/H narrow bore column (Boehringer Mannheim GmbH, Germany), using aqueous 
acetonitrile/trifluoroacetic/acid solvents and a Shimadzu HPLC system equipped with LC-10AD pumps, SCL-
10A system controller, CTO-10AC oven, FRC-10A fraction collector and SPD-M10AV diodearray detector. The 
gradient of buffer B (0.1% trifluoroacetic acid in acetonitrile) was: 10–36.5%, 12 min; 36.5–37%, 4 min; 37–41%, 
7 min; 41–70%, 12 min; and 70%, 5 min. A temperature of 55 °C was maintained during HPLC separation. Peaks 
were detected by UV absorption at 206 nm and 280 nm. Fractions containing HIV-1 BAL/SUP-T1-R5 gp120 were 
lyophilized for further SDS-PAGE purification.
SDS-PAGE purification of viral gp120 protein. In adjacent gel lanes, gp120 purified from the HIV-1 
BAL/SUPT1-R5 viral samples by HPLC and the viral samples disrupted in 2x sample buffer were loaded on a 
1.5 mm thick 4–20% Tris glycine gel (Invitrogen, Carlsbad, CA). The samples were separated by SDS-PAGE, 
followed by staining with Coomassie R-250. After destaining the gp120–containing bands were excised and trans-
ferred in tubes with 1% acetic acid solution.
Production of gp120 tryptic glycopeptides by in-gel digestion. Excised bands corresponding to 
gp120 were first destained in a 50% acetonitrile (MeCN) (v/v) solution in 0.1 M ammonium bicarbonate for 
10 min, followed by incubation with 10 mM dithiothreitol (DTT) solution for 30 min at 56 °C. The gel pieces were 
then desiccated prior to incubation with a 55 mM solution of iodoacetic acid for 30 min at room temperature 
in the dark. The gel pieces were desiccated again prior to incubation with 1 μ g of porcine trypsin (EC: 3.4.21.4, 
Promega) in 50 mM ammonium bicarbonate, pH 8.5 (adjusted with ammonia), overnight at 37 °C. Following 
extraction of the tryptic glycopeptides from the gel in acetonitrile/0.1% trifluoroacetic acid (6:4 v/v), the eluent 
volumes were reduced to approximately 10 μ L under vacuum36,37. The overall methodological approach used is 
summarised in Fig. 3.
Glycomic analyses. For glycomic experiments, the tryptic peptide/glycopeptide digest mixture was first 
subjected to enzymatic release of the N-glycan populations, before being purified, derivatised and analysed by 
MALDI-TOF-MS and MS/MS. The overall glycomic analytical approach is summarised in the upper half of 
Fig. 3 38–40.
N-linked glycan release by PNGase F. Aliquots of the reduced, carboxymethylated and trypsin-digested gel 
extracts were diluted by the addition of 200 μ L fresh 50 mM ammonium hydrogen carbonate, pH 8.4 (adjusted 
with ammonia). 0.5U of N-glycosidase F (PNGase F) in glycerol (Roche EC 3.5.1.52) were then added and the 
sample incubated at 37 °C overnight before being terminated by lyophilisation.
N-linked glycan release by PNGase A. Aliquots of the reduced, carboxymethylated and trypsin-digested gel 
extracts were diluted by the addition of 200 μ L fresh 50 mM ammonium acetate, pH 5.0 (adjusted with acetic 
acid). 0.5U of N-glycosidase A (PNGase A) in glycerol (Roche EC 3.5.1.52) were then added and the sample 
incubated at 37 °C overnight before being terminated by lyophilisation.
N-linked glycan release by Endo H. Aliquots of the reduced, carboxymethylated and trypsin-digested gel extracts 
were diluted by the addition of 200 μ L 50 mM ammonium hydrogen carbonate, pH 8.4 (adjusted with ammonia). 
0.5U of Endoglycosidase H (Endo H) (Roche EC 3.2.1.96) were then added, together with 5 μ L of supplied Endo 
H Reaction Buffer. The reaction was then incubated at 37 °C overnight before being terminated by lyophilisation.
Separation of released glycans from peptides. Released glycans were separated from residual peptides using a 
reverse-phase C18 Sep-Pak cartridge. The Sep-Pak was conditioned successively with methanol, 5% acetic acid 
(aq., v/v), propan-1-ol, and 5% acetic acid. The sample was dissolved in 5% acetic acid, loaded onto the cartridge, 
and eluted successively with 5% acetic acid followed by 20%, 40%, 60% and 100% propan-1-ol in 5% acetic acid 
(v/v). The organic solvent was removed on a Savant Speed-Vac concentrator (ThermoFisher Scientific Inc.) and 
samples were lyophilized prior to permethylation.
Permethylation of released glycan pools. Permethylation was performed using the sodium hydroxide procedure41. 
Briefly, sodium hydroxide pellets were crushed with dimethyl sulfoxide (DMSO) to form a slurry. A 1 mL aliquot 
of this slurry was added to the dried glycans, followed by the addition of 1 mL of methyl iodide (ICH3). The mix-
ture was vigorously mixed on an automatic shaker for 10 min at room temperature42. The reaction was terminated 
by the addition of 1 mL of water, and permethylated glycans were recovered by chloroform extraction. The chloro-
form layer was washed several times with water in order to remove impurities and was then dried under a stream 
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of nitrogen. Permethylated N-glycans were purified using a reverse-phase C18 Sep-Pak cartridge. The Sep-Pak 
was conditioned successively with methanol, water, acetonitrile (MeCN), and water. The sample was dissolved 
in 1:1 (v/v) methanol-water, loaded onto the cartridge, washed with water and 15% (v/v) aqueous MeCN solu-
tion, and then eluted using a 75% (v/v) aqueous MeCN solution. The organic solvent was removed on a Savant 
Speed-Vac concentrator and samples were lyophilized prior to MALDI-TOF-TOF-MS and MS/MS analyses.
MALDI-TOF mass spectrometry of permethylated glycans. MALDI-TOF-MS data on permethylated samples 
were acquired in the reflector positive-ion mode using a 4800 MALDI-TOF/TOF (Applied Biosystems, Foster 
Figure 6. Complete gp160 amino acid alignment of HIV-1 BaL/SupT1-R5. BAL.AY713409 is the published 
reference sequence (GenBank accession number AY713409). Dashed lines show sequence identity to the 
reference sequence and amino acid polymorphisms are indicated by a single letter amino acid abbreviation. Key 
landmarks in gp160 are denoted above each region. Potential N-linked glycosylation sites are shaded. In two 
sequences (H11 and E1), a nucleotide frame shift lead to a premature stop codon (*). In a third sequence (C12) a 
nucleotide change in W754 also led to a premature stop codon (*).
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City, CA) mass spectrometer. The instrument was calibrated externally using the Calmix 4700 calibration stand-
ard, containing des-Arg1-bradykinin, angiotensin I, human [Glu1]-fibrinopeptide B, adrenocorticotropin 
(ACTH) fragment 1–17, ACTH fragment 18–39 and ACTH fragment 7–38. Samples were dissolved in 20 μ L of 
methanol, and 1 μ L was mixed at a 1:1 ratio (v/v) with 2,5-dihydrobenzoic acid (20 mg/mL in 50% (v/v) meth-
anol in water) as a matrix. Then samples were spotted onto a 384-well sample plate and were dried under a vac-
uum. Data were acquired using 4000 Series Explorer instrument control software and were processed using Data 
Explorer MS processing software. MS spectra were assigned and annotated with the help of the GlycoWorkbench 
software43,44.
Glycoproteomic analyses. For glycoproteomic experiments the tryptic peptide/glycopeptide gp120 
digest mixture (see earlier) was analysed directly by on-line nano-LC-MS and MS/MS by electrospray ionisation 
(see Nano-LC ES-MS and MS/MS analysis of glycopeptides) and by MALDI via auto-spotted plates, or first sub-
jected to N-linked glycan release by Endo H or PNGase F and/or sub digestion with additional proteases prior to 
analysis. The overall Glycoproteomic approach is summarised in the lower half of Fig. 3 36,45–49. Methods used for 
the proteolytic sub-digestions are presented below.
Glu-C sub digestion. Aliquots of the reduced, carboxymethylated, trypsin-digested gel extracts, following 
treatment by Endo H were digested with 1 μ g of Endoproteinase Glu-C from Staphylococcus aureus strain V8 
(EC:3.4.21.19) in 20 μ L of 50 mM Tris (pH 8.0). The reaction was then incubated at 37 °C overnight before being 
terminated by lyophilisation.
Chymotrypsin sub digestion. Aliquots of the reduced, carboxymethylated, trypsin-digested gel extracts, follow-
ing treatment by Endo H were digested with 1 μ g of chymotrypsin from bovine pancreas (EC:3.4.21.4, Sigma) in 
20 μ L of 50 mM ammonium hydrogen carbonate (pH 8.4). The reaction was then incubated at 37 °C overnight 
before being terminated by lyophilisation.
Offline nano-LC-MALDI-TOF mass spectrometry of glycopeptides. Glycopeptide pools were dissolved in 40 μ L 
0.1% (v/v) trifluoroacetic acid (TFA) and separated by nano-LC using an Ultimate 3000 (Thermo Scientific 
Dionex (UK) Ltd, Camberley) fitted with a Pepmap analytical C18 nanocapillary column. After loading in 2% 
(v/v) acetonitrile in 0.1% TFA (v/v), the column was eluted with a gradient of acetonitrile in 0.1% TFA at a flow 
rate of 0.3 μ L/min. Sample elutions were spotted directly onto a steel MALDI target plate using a Probot system 
(Thermo Scientific Dionex (UK) Ltd, Camberley) with α -cyano-4-hydroxycinnamic acid matrix at a concentra-
tion of 3.3 mg/mL. Peptides were subjected to MALDI-MS profiling, complemented with MS/MS sequencing of 
the 10 most abundant ions in each sample, on an Applied Biosystems 4800 MALDI-TOF/TOF mass spectrometer 
(Applied Biosystems, Foster City, CA) operated in reflector positive-ion mode. The instrument was calibrated 
externally using the Calmix 4700 calibration standard. Data were acquired using 4000 Series Explorer instrument 
control software and were processed using Data Explorer MS processing software.
Nano-LC ES-MS and MS/MS analysis of glycopeptides. The gp120 tryptic digest mixture, or collected glyco-
peptide pools from initial runs resuspended in 0.1% (v/v) TFA, were analysed by nano-LC-ES-MS/MS using a 
nano-high-performance liquid chromatography (HPLC) system (Thermo Scientific Dionex (UK) Ltd, Camberley) 
connected to a quadrupole TOF49 mass spectrometer (API Q-STAR® Pulsar i, Applied Biosystems/MDS Sciex, 
Toronto, Canada). Separations were achieved by means of a 75 μ m C18 reverse-phase column eluted with a gradi-
ent of acetonitrile in 0.01% formic acid at a flow rate of 200 nL/min. Data-dependent acquisition of MS/MS spectra 
was controlled by setting threshold ionization values for doubly, triply, and quadruply charged ions, and colli-
sion energies were set to produce good fragmentation. The instrument was pre-calibrated using 10–100 fmol/μ L 
of [Glu1]-fibrinopeptide B /5% (v/v) acetic acid (1:3, v/v). In the MS/MS mode, the collision gas utilized was 
nitrogen and the pressure was maintained at 5.3 × 10−5 Torr. Data acquisition was performed using Analyst QS 
(Applied Biosystems, Darmstadt, Germany) software with an automatic information-dependent-acquisition 
function.
Interpretation of glycoproteomic data. This was done manually as previously described36,45–49 and is exemplified 
by the representative data shown in Supplementary Figures S2–S6. The spectra shown in this figure illustrate the 
good quality of the MS/MS data, despite the low ion counts of many of the glycopeptide molecular ions, an inev-
itable consequence of the limited amounts of sample available. Key elements of the logic associated with manual 
interpretation of MS/MS data is contained in the legend to Supplementary Figures S2–S6.
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